pharma · Prostate Cancer · Autoimmune · JANX
Janux Therapeutics
Janux Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker JANX. Primary therapeutic focus areas include Prostate Cancer, Autoimmune, Non-Small Cell Lung Cancer. NovaPharm
San Diego, USA HQ
2017 Founded
110 Employees
Public company Type
JANX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2017
- Employees
- 110
- Programs
- 4
- Drugs
- 0
- Patents
- 2
JANX007
Phase 1 · mab · Prostate Cancer
JANX007 for Prostate Cancer is a Phase 1 program (mab) at Janux Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code PSMA-007-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janux Therapeutics
- Phase
- Phase 1
- Modality
- mab
- Indication
- Prostate Cancer
- Status
- active
- Trials
- 1